May
29
2021

Anti-Viral Photodynamic Therapy (PDT) Can Treat Covid-19 Successfully

A German research team wanted to test whether an anti-viral photodynamic therapy (PDT) can treat Covid-19 successfully. They went to Tehran during the first Covid-19 peak in 2020 and did the following experiment.

All patients of the clinical trial were in the early stage of Covid-19. The researchers compared 20 patients (experimental group who had photodynamic therapy) with 20 patients that served as a control.

Results of the study

The results were as follows (initial symptoms compared to 5 days later):

  • 18 patients had a high fever, but 5 days after PDT they were afebrile
  • 17 patients had a severe cough; after 5 days of PDT only 6 patients did
  • There were 19 patients initially with breathing problems. After 5 days of PDT only 5 patients still had acute breathing problems.
  • Less severe symptoms like headaches, sleep disturbance and fatigue initially improved rapidly with PDT in about half of the patients.

It is interesting to note that none of the control group patients showed signs of improvements of the Covid-19 symptoms. Two patients of the control group had to be transferred into the ICU ward of a hospital. None of the control patients showed a reduction of the viral load.

PCR testing to verify effectiveness of anti-viral photodynamic therapy

A highly specific and sensitive polymerase chain reaction with the name QPCR determines the viral RNA in the subject. The researchers measured the QPCR daily in every subject. On day 1 only 8 patients had a QPCR value of 30 or more. In contrast, on day 5 there were 14 subjects who tested negative for the SARS-CoV-2 virus and 5 patients had a QPCR value of more than 30. A value of more than 30 was considered to indicate a low virus concentration. Expressed in another way, 95% of 20 patients were cured of Covid-19, while 100% of the control group deteriorated because of the SARS-CoV-2 virus.

How does the antiviral phototherapy work?

Photodynamic therapy (PDT) has shown to be effective in the past against bacteria, parasites and viruses. An important application in transfusion medicine is the inactivation of viruses and bacteria in stored red blood cell units. The laboratory physician adds a small amount of vitamin B2 (riboflavin) to red blood cell units. Treatment with ultraviolet light for a short period follows, which inactivates viruses and bacteria. Vitamin B2 is harmless and does not need removal.

The same technique was effective to remove Middle East respiratory syndrome coronavirus (MERS-CoV) from plasma products.

Researchers from the Colorado State University combined riboflavin and UV radiation to clear the SAARS-CoV-2 virus from plasma and platelets successfully.

Activation of riboflavin by UV light and blue light kills the SARS-CoV-2 virus

Riboflavin, which also goes by the name vitamin B2, is a photosensitizer. The light absorption of riboflavin is in the 375 nm (UVA light) and in the 450 nm (blue light) range. Dr. Weber, an internist and engineer from Germany showed that you can use UVA light and blue light to activate riboflavin. Laser light stimulation of riboflavin releases reactive oxygen species (ROS), which damages the virus proteins, lipids and nucleic acids. The patient takes 100 mg of riboflavin-5-phosphate orally. In addition, the patient also sprays a riboflavin solution to the inside of the nose and on the tongue.

Laser applicators cause riboflavin to release oxygen species (ROS)

Special laser applicators for the nose and for the mouth/throat produce a mix of UVA and blue laser light. This stimulates riboflavin from the blood in these regions to release reactive oxygen species. In addition, the patient applies a special laser watch (the name of it is “Laser Watch Spectra”) to the volar aspect of the wrist. This watch is sold by Weber Medical Systems GmbH, Germany. The location of the ulnar and radial arteries is at the volar aspect of the wrist. When the wrist watch is applied there, the riboflavin in the blood stream of the arteries releases oxygen species (ROS). This in turn kills the Covid-19 coronavirus.

Antiviral phototherapy to eradicate the SARS-CoV-2 virus in humans

A German research team under Dr. Weber went to Tehran, Persia during the first SARS-CoV-2 virus epidemic. They did a pilot study to show that photodynamic therapy can treat Covid-19 successfully. They divided 40 confirmed Covid-19 patients in an early stage into two groups. 20 patients were the treatment group and the other 20 patients made up the control. As already discussed before there were striking differences in the treatment group versus the control group. The procedure was simple.

Treatment regimen

First the patient takes 100 mg of vitamin B2 (as Roboflavin-5-phosphate). 15 to 30 minutes later vitamin B2 is circulating in the blood. The patient now attaches the laser wrist watch to one of the wrists and the mouth/throat applicator for 1 hour. The next application is a nose applicator for 1 hour. This completes the laser treatment for the day. The patients received the same treatment 5 days in a row. As the tables of the first link showed the treatment group experienced significant healing from Covid-19. The control group did not, but rather deteriorated.

Anti-Viral Photodynamic Therapy (PDT) Can Treat Covid-19 Successfully

Anti-Viral Photodynamic Therapy (PDT) Can Treat Covid-19 Successfully

Conclusion

A combined UVA laser and a blue laser treatment matching the light absorption of riboflavin cured 95% of Covid-19 patients. A German research group under Dr. Weber went to Tehran, Persia in the middle of the first Covid-19 wave. An experimental group received laser treatment of the nasal passages and the tongue and throat for 1 hour each. In addition, the researchers treated the ulnar and radial arteries with UVA and blue laser light as well. This treated any coronaviruses that leaked into the general circulation.

Cure of Covid-19 in 5 days

After only 5 days of this therapy there was a 95% cure of Covid-19. In contrast, 100% of the control group without laser treatment remained very symptomatic. Two patients of the control group required transfer into the ICU. None of the control patients showed a reduction of the viral load while 95% of the treatment group did. In the meantime, the researchers repeated the experiment with 50 patients in each group and obtained the same result (personal communication from Dr. Weber).

This is the first time that a research group was able to report a cure for Covid-19.

About Ray Schilling

Dr. Ray Schilling born in Tübingen, Germany and Graduated from Eberhard-Karls-University Medical School, Tuebingen in 1971. Once Post-doctoral cancer research position holder at the Ontario Cancer Institute in Toronto, is now a member of the American Academy of Anti-Aging Medicine (A4M).

Speak Your Mind

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.